April 23, 2015 POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it ha - Progression-free survival - Document - PDFSEARCH.IO

First Page	Meta Content
	April 23, 2015 POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it ha Add to Reading List Document Date: 2015-12-12 00:14:44 Open Document File Size: 66,31 KB Share Result on Facebook

April 23, 2015 POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it haAdd to Reading List